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Association of maternal diabetes/glycosuria
and pre-pregnancy body mass index with
offspring indicators of non-alcoholic fatty
liver disease
Sumaiya Patel1, Debbie A. Lawlor2, Mark Callaway3, Corrie Macdonald-Wallis2, Naveed Sattar4 and Abigail Fraser2*
Abstract
Background: Little is known about early life determinants of non-alcoholic fatty liver disease (NAFLD). We examined
associations of maternal pregnancy diabetes/glycosuria and pre-pregnancy body mass index (BMI) with offspring
markers of NAFLD and liver pathology and examined mediation by birthweight and concurrent offspring adiposity.
Methods: We used data from a UK prospective pregnancy cohort. Offspring underwent abdominal ultrasonography
(USS) at mean age 17.8 years. Outcomes included USS-assessed fatty liver, estimated liver volume and shear velocity,
a variant of elastography (a marker of liver fibrosis) (N = 1 215) and blood-based markers of liver pathology [alanine
amino transferase, aspartate amino transferase, gamma- glutamyltransferase and haptoglobin] (N = 2 359).
Results: 2.1 % (N = 25) of participants had USS-assessed fatty liver [maternal diabetes/glycosuria (N = 7) and no
diabetes/glycosuria (N = 18)]. Maternal diabetes/glycosuria was associated with greater odds of offspring USS fatty liver
in confounder adjusted models [adjusted odds ratio (aOR) 6.74 (95 % confidence interval (CI) 2.47, 18.40)] and higher
shear velocity [adjusted ratio of geometric mean (aRGM):1.10 (95 % CI 1.05, 1.15)]. These associations were not
mediated by offspring birthweight or concurrent adiposity. Maternal diabetes/glycosuria was not associated with liver
volume or blood-based outcomes. Greater maternal pre-pregnancy BMI was associated with greater odds of offspring
USS fatty liver [aOR 2.72 (95 % CI: 1.20, 6.15)], higher liver volume [aRGM 1.03 (95 % CI 1.00, 1.07)] and shear velocity
[aRGM1.03 (95 % CI: 1.01, 1.06)] in confounder adjusted models. These associations were largely mediated by offspring
adiposity. Maternal pre-pregnancy BMI was not consistently associated with blood-based outcomes.
Conclusions: Results suggest that maternal pregnancy diabetes/glycosuria is associated with offspring NAFLD through
mechanisms other than offspring’s own adiposity.
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Background
The developmental overnutrition hypothesis suggests that
maternal pregnancy diabetes and adiposity are character-
ized by increased delivery of fuels such as glucose, free fatty
acids and amino acids to the developing fetus [1, 2]. This
results in greater offspring birthweight and altered neuro-
endocrine, pancreatic, hepatic or musculoskeletal systems,
which in turn lead to greater offspring adiposity and a more
adverse cardiometabolic health profile later in life [1, 2].
Several studies have reported associations of maternal pre-
pregnancy body mass index (BMI) and pregnancy diabetes
with long term adverse cardiometabolic outcomes in the
offspring, including obesity [3, 4], glucose metabolism and
dyslipidemia [5, 6]. This includes reports based on data
from the Avon Longitudinal Study of Parents and Children
(ALSPAC), which we use here [7–9].
Non-alcoholic fatty liver disease (NAFLD) is closely
associated with greater adiposity, hyperlipidemia and hyper-
insulinemia [10], diabetes [11] and is considered the hepatic
manifestation of the cluster of metabolic abnormalities
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linked to insulin resistance. Hence it is plausible that expos-
ure to diabetes and increased maternal adiposity in utero
may be associated with a greater risk of NAFLD later in life.
In animal models, maternal high fat diets [12] and maternal
obesity [13, 14] during pregnancy, predisposes the develop-
ing offspring to non-alcoholic steatohepatitis and insulin
resistance.
Two recent studies in humans have examined the associ-
ations of maternal pre-pregnancy BMI [15] and gestational
diabetes [16] with infant offspring intrahepatocellular lipid
content (IHCL) assessed by magnetic resonance spectros-
copy. Modi and colleagues [15] reported an increase of
8.6 % (95 % confidence intervals [CI], 1.1, 16.8) in IHCL at
a mean age of 11.7 days per maternal BMI unit in-
crease (N = 105). Although due to the small number of
mothers with gestational diabetes in the study sample they
were unable to examine its independent effect. Brum-
baugh et al. [16] reported greater IHCL content in infants
aged 1–3 weeks born to obese diabetic mothers (N = 10)
compared to infants of non-diabetic, non-obese women
(N = 10). However, this study did not look at the associ-
ation of maternal obesity and gestational diabetes separ-
ately and whether associations seen in infants persist in
older ages remains unclear.
The principal aim of this study is to examine associa-
tions of maternal pregnancy diabetes/glycosuria and pre-
pregnancy BMI with offspring markers of NAFLD and
liver pathology [ultrasound scan (USS) assessed fatty liver,
estimated liver volume and stiffness (a marker of liver fi-
brosis) and fasting blood alanine amino transferase (ALT),
aspartate amino transferase (AST), gamma- glutamyl-
transferase (GGT) and haptoglobin] in adolescence.
The main outcome is USS assessed liver fat. We further
aim to explore whether any associations are mediated
by birthweight and/or offspring’s own concurrent adi-
posity. Figure 1 shows the pathways examined in this
study.
Methods
Study participants
The Avon Longitudinal Study of Parents and Children
(ALSPAC) is a prospective, population-based birth cohort
study that recruited 14 541 pregnant women residing in
Avon, UK, with expected dates of delivery 1st April 1991 to
31st December 1992 (http://www.alspac.bris.ac.uk) [17, 18].
From age seven, offspring have been invited to designated
research clinics. At the 17–18 year clinic a sub-sample of 1
874 offspring completed liver ultrasound scans (USS) and 3
069 had blood samples taken. For this study mother-
offspring duos with data on exposures (pregnancy diabetes/
glycosuria and maternal pre-pregnancy BMI) and outcomes
(measures from liver USS, ALT, AST, GGT and haptoglo-
bin) were eligible (see Fig. 2). No participants had a known
history of jaundice or hepatitis, were taking medications or
receiving treatment that would indicate they had hepatic
disease, or were taking medication known to influence liver
function. In order to remove any effect of fat infiltration in
the liver due to excess alcohol intake, consistent harmful
alcohol drinkers were removed from the analysis. Informa-
tion on offspring’s alcohol consumption was obtained the
Alcohol Use Disorders Identification Tests questionnaire
[19]. This was administered to offspring at 16 years, and
17 years (at the same time as the USS assessment) and
participants were scored between 0 and 20 with a score
over 16 being classified as harmful alcohol consumption
[19]. Consistent harmful alcohol drinkers were defined by a
score of 16 or greater at both 16 and 17 years. After re-
moval of 42 participants classified as consistent harmful
drinkers 1 215 had complete data on exposures, covariables
and USS outcomes and 2 359 had complete data on expo-
sures, covariables and blood-based outcomes (ALT, AST,
GGTand haptoglobin) (see Fig. 2).
Ethical approval for this study was obtained from the
ALSPAC Law and Ethics Committee and the North Somer-
set & South Bristol National Health Service Research Ethics
Committee (09/H0106/53). All participants (mothers and
offspring) provided written informed consent.
Assessment of maternal characteristics
The methods used to determine maternal pregnancy dia-
betes and glycosuria have been described in detail previ-
ously [7, 8]. Briefly, information on existing diabetes was
collected by questionnaire from women at the time of
recruitment. A standard protocol was used by research
midwives to obtain information on a clinical diagnoses of
gestational diabetes and glycosuria (recorded as none, trace,
+, ++,+++ or more) for the index pregnancy from the
woman’s antenatal and postnatal medical records. The mid-
wives searched all aspects of these records and gestational
diabetes was defined as any record of a diagnosis of gesta-
tional diabetes at any time during the pregnancy in women
without existing diabetes at the start of pregnancy.
The practice in the UK at the time when mothers were
recruited (April 1991 to December 1992) was for all women
to be offered urine tests for glycosuria at each antenatal
clinic visit. Universal screening was not undertaken and
diagnostic tests for gestational diabetes, which could have
included a fasting glucose or an oral glucose tolerance test,
will only have been undertaken in women with established
risk factors (obesity, family history of diabetes and previous
history of gestational diabetes or macrosomic birth, south
Asian ethnicity) or glycosuria. Glycosuria in our study was
defined as a record of at least ++ (equal to 13.9 mmol/l or
250 mg/100 ml) on at least two occasions at any time
during the pregnancy in the absence of existing diabetes
and gestational diabetes. These three categories of maternal
existing diabetes, maternal gestational diabetes and mater-
nal glycosuria were combined in the main analysis due to
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the small number of offspring with outcome data in each of
the categories (N = 7, N = 8 and N = 47 respectively).
Median and interquartile range for age at diagnosis of the
existing diabetes group was 12.5 years (9.0, 25.0). This early
age of diagnosis suggests that this group would be predom-
inantly type I diabetes. In this study women were catego-
rized as having any of existing diabetes, gestational diabetes
or glycosuria in pregnancy or not; this status is referred
to as diabetes/glycosuria throughout the remainder of
the paper.
Maternal self-reported weight and height determined
by postal questionnaire at 12 week gestation were used
to calculate pre-pregnancy BMI. Maternal self-reported
weight correlated highly with the mother’s weight meas-
urement at the first antenatal visit (r = 0.95). Maternal
pre-pregnancy BMI was categorised as underweight/nor-
mal (BMI <25.0 kg/m2) and overweight/obese (BMI
≥25.0 kg/m2).
Liver ultrasound scans and blood-based outcomes
For both the liver USS and all blood-based analyses partic-
ipants were fasted overnight for those attending clinic in
the morning, or for a minimum of 6 h, for those attending
clinic after lunch.
Liver ultrasound scans
A detailed description of the liver ultrasound scans has
been published previously [20].
Briefly, upper abdominal USS was completed by one
of four trained sonographers using a Siemens Acuson
S2000 USS system, with the participant at rest in the
dorsal decubitus position. Echogenicity (a marker of liver
fat) was assessed during deep inspiration and recorded
as present, absent or uncertain according to established
protocols using the right kidney as the reference organ
[21].
Acoustic radiation force impulse-imaging (ARFI) of
the right lobe of the liver was used to measure liver stiff-
ness (or fibrosis), using standard protocols [22, 23] and
this was used as our main indicator of liver fibrosis. The
right lobe of the liver was viewed through the intercostal
space such that the pulse wave was traversing an area of
at least 6 cm and was not traversing any major vascular
structures and the right lobe was clearly viewed.
Estimated liver volume was assessed by three transversely
(lateral to medial), from diaphragm down to the inferior
pole of the liver (cranio-caudal) and back to front (posterior
to anterior) sweeps through the liver.. These produced dis-
tances, which were used to calculate liver volume with the
Siemens Acuson S2000 system software.
Blood-based outcomes
Fasting blood samples were immediately spun and fro-
zen at −80 °C. Measurements were assayed shortly (3–9
months) after with no previous freeze-thaw cycles. All
assays were completed in the same laboratory (University
of Glasgow). ALT, GGT and AST were measured by auto-
mated analyser with enzymatic methods and haptoglobin
was measured by immunoturbidimetry.
Other variables
Maternal age, parity, gestational age, birthweight and off-
spring gender were extracted from medical records. Paren-
tal occupation was used to derive household occupational
social class, with each household assigned the highest
parental occupational (classes I (professional/managerial) to
Fig. 1 Pathways related to the associations between maternal pre-pregnancy adiposity and maternal pregnancy diabetes/glycosuria with offspring NAFLD.
The dark arrows represent the main association of interest in the paper. The dashed arrows are the possible pathways for the underlying mechanism and
which are examined in this study
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V (unskilled manual workers), using the 1991 British Office
of Population and Census Statistics classification). Maternal
pre-pregnancy alcohol consumption was determined by a
postal self-completed questionnaire at 18 weeks gestation
and was categorised as less than or more than one glass
(described in one unit portions within the questionnaire) of
alcohol per week. Offspring age at clinic was recorded in
months. Offspring height was measured without shoes to
the nearest 0.1 cm using a Harpenden stadiometer. A
Lunar prodigy narrow fan beam densitometer was used to
perform a whole body DXA scan from which fat mass was
measured as described previously [24].
Statistical analysis
Analysis was conducted using Stata version 12.0 MP2
(Stata Inc., TX, USA).
The distributions of shear velocity, liver volume, AST,
AGT, GGT and haptoglobin were positively skewed but
with a natural log transformation were approximately
normally distributed. We use medians and interquartile
range to describe these variables and natural logged values
in multivariable models. Birthweight was standardized by
gestational age in completed weeks, using the cohort gesta-
tional age distribution.
A series of multivariable regression models were con-
structed in order to examine the associations between
maternal characteristics and offspring outcomes and to ex-
plore the impact of adjustment for potential confounding
and mediating factors. For USS-determined fatty liver
results are presented as odds ratio and 95 % confidence
intervals and for liver volume, shear velocity, ALT, AST,
GGT and haptoglobin results are presented as ratio of
geometric means and 95 % confidence intervals and were
obtained by back transforming coefficients.
Maternal-offspring pairs were included in the multivari-
able analyses if they had complete data on all variables used
Fig. 2 Participants’ flow diagram through the study and the numbers included in each of the main analyses
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in any model. Therefore numbers vary between USS out-
comes and blood-based outcomes but are the same across
models for each outcome (N = 1 215 and N = 2 359 respect-
ively). Confounders and/or mediators to be included in the
models were decided upon a priori. We considered the
following potential confounders: maternal age at delivery,
parity, maternal pre-pregnancy alcohol intake, household
social class and maternal pre-pregnancy BMI. Potential
mediators were birthweight and offspring concurrent fat
mass.
Whilst offspring measures of lipid and glucose metabol-
ism are closely associated with NAFLD as previously shown
in this population [20], they cannot be confounders here as
the exposure of interest (i.e. maternal diabetes/glycosuria)
precedes these. Moreover, as the direction of their relation-
ship with NAFLD (cause, consequence or both) remains
unclear, adjusting for these may constitute adjusting for a
common effect which would bias results [25].
In the basic model (model 1) we controlled for offspring
age at the time of outcome assessment and gender. In the
confounder adjusted model (model 2) we additionally ad-
justed for the potential confounding by maternal age at
delivery, parity, maternal pre-pregnancy alcohol intake,
household social class, and when considering pregnancy
diabetes/glycosuria as the exposure we additionally adjusted
for maternal pre-pregnancy BMI. In model 3 we also ad-
justed for possible mediation by birthweight for gestational
age and in model 4 we considered mediation by offspring’s
concurrent adiposity by adjusting for DXA assessed fat
mass, height and height squared (assessed at the 17–18 year
clinic). In sensitivity analyses, we examined whether adjust-
ment for offspring concurrent BMI instead of DXA-
assessed fat mass altered the associations examined
(N = 1 215 for USS outcomes and 2 358 for blood-
based outcomes).
Results
Table 1 shows the characteristics of mother-offspring pairs
included in the analysis of either USS or blood-based out-
comes, compared to mother-offspring pairs who are not
included in either analyses but who attended the 17–18
year clinic, and to cohort members who did not attend the
17–18 year clinic. Of the 2 753 mother-offspring pairs who
were included in either analyses of USS (N = 1 215) or
blood-based outcomes (N = 2,359), 18.9 % of the mothers
were overweight or obese and 4.1 % of mothers had preg-
nancy diabetes or glycosuria. Of the 1 215 offspring in-
cluded in analyses, 2.1 % (N = 25) had USS fatty liver.
Mothers of offspring who attended the 17–18 year clinic
but were not included in either analyses (mainly due to
missing outcome data) were younger, consumed less alco-
hol before pregnancy and were more likely to be from a
lower social class household compared to those who were
included in analyses. Offspring who attended the 17–18
year clinic but were not included in analyses had a lower
mean birthweight and greater mean fat mass compared to
those offspring who were included in analyses. Mothers of
offspring who did not attend the 17–18 year clinic had a
higher pre-pregnancy BMI, were younger, had more previ-
ous pregnancies, consumed less alcohol during pregnancy
and were more likely to be from a manual social class
household compared to the mothers of offspring who were
included in either analyses. Offspring who did not attend
clinic at age 17–18 years were more likely to be male and
had a lower mean birthweight compared to those included
in either USS or blood-based analyses (Table 1).
Table 2 shows the multivariable associations of maternal
pregnancy diabetes/glycosuria with offspring outcomes.
Offspring whose mothers had pregnancy diabetes/glyco-
suria were more likely to have USS fatty liver and had a
higher mean shear velocity in the age and gender adjusted
model (model 1). Adjustment for potential confounding
factors (including maternal pre-pregnancy BMI), did not
notably alter these associations. Further adjustment for
potential mediation by offspring birthweight (model 3) or
later offspring adiposity (model 4) did not markedly change
the magnitude of these associations. In the confounder and
mediator adjusted model, exposure to diabetes/glycosuria
in utero was associated with more than a 6-fold increase in
the risk of having a fatty liver compared to offspring of
mothers with no pregnancy diabetes/glycosuria during
pregnancy. There was no evidence of an association for
maternal pregnancy diabetes/glycosuria with liver volume,
fasting blood ALT, AST, GGT or haptoglobin in any of the
multivariable models.
Table 3 shows the multivariable associations of maternal
pre-pregnancy obesity and BMI with offspring outcomes.
Offspring of overweight/obese mothers were more than
twice as likely to have USS fatty liver, and had greater liver
volume and higher shear velocity in the basic and con-
founder adjusted models (models 1 and 2) compared to
offspring of underweight/normal weight mothers. This
association remained when offspring birthweight was
added to the model as a potential mediator (model 3),
whilst associations were attenuated to the null when
adjusting for offspring concurrent fat mass (model 4). The
association of maternal overweight/obesity with liver
volume was attenuated in both mediator adjusted models
(model 3 and 4). There was no strong evidence of an asso-
ciation of maternal pre-pregnancy overweight/obese with
ALT, AST, GGT or haptoglobin in any of the multivariable
models. Similar patterns of association were seen when
considering maternal pre-pregnancy BMI as a continuous
exposure (per SD change in pre-pregnancy BMI).
Additional file 1: Table S1 shows the distribution of out-
comes across the four categories of maternal pre-existing
diabetes, gestational diabetes, glycosuria and no mater-
nal diabetes/glycosuria and the univariable associations
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Table 1 Comparison of maternal and offspring characteristics of participants who were included in either the USS based outcomes
and/or blood-based outcome analyses, to participants not included in either analyses but attended clinic at age 17–18 years and to
those who did not attend the clinic at age 17–18 years
Characteristic Included in either analysis
of blood-based or USS
outcomes (reference group)
Attended 17–18 year clinic but
not included in either analysis
Did not attend 17–18 year clinic
N Mean (SD) or median
(IQR) or N (%) as
indicated
N Mean (SD) or median
(IQR) or N (%) as
indicated
P value* N Mean (SD) or median
(IQR) or N (%) as
indicated
P value*
Maternal
Pre-pregnancy BMI
(mean, SD)
2 753 22.8 (3.7) 1 520 23.0 (3.7) 0.15 6,940 23.0 (4.0) 0.01
Pre-pregnancy BMI
(N, %)
2 753 1 520 0.15 6,940 0.004
Underweight/Normal 2 234 (81.2) 1 206 (79.3) 5,451 (78.4)
Overweight/Obese 519 (18.9) 314 (20.7) 1,489 (21.5)
Diabetes status (N, %) 2 753 1 770 0.98 7,480 0.93
No diabetes or
glycosuria
2 639 (95.9) 1 697 (95.9) 7 173 (95.9)
Existing diabetes/
Gestational diabetes/
Glycosuria
114 (4.1) 73 (4.1) 307 (4.1)
Maternal age (years)
(mean, SD)
2 753 29.5 (4.5) 1 953 28.8 (4.7) <0.001 8,864 27.3 (5.0) <0.001
Parity (N, %) 2 753 1 797 0.99 8,003 <0.001
0 1 326 (48.2) 866 (48.2) 3 444 (43.0)
1 988 (35.9) 591 (32.9) 2 801 (35.0)
2+ 439 (16.0) 340 (18.9) 1 758 (22.0)
Pre pregnancy alcohol
intake (N, %)
2 753 s <0.001 8,071 <0.001
<1 glass per week 1 141 (41.5) 863 (46.8) 3 833 (47.5)
1+ glass per week 1 612 (58.6) 980 (53.2) 4 238 (52.5)
Family social class
(N, %)
2 753 1 594 <0.001 6,829 <0.001
Non-manual 2 432 (88.3) 1 344 (84.3) 5 228 (76.6)
Manual 321 (11.7) 250 (15.7) 1 601 (23.4)
Offspring
Age (months) (mean,
SD)
2 753 213.5 (4.7) 1 864 213.5 (5.3) 0.97
Male (N, %) 2 753 1 300 (47.2) 1 953 676 (39.3) <0.001 8,862 4 938 (55.7) <0.001
Gestational age
(weeks) (mean, SD)
2 753 39.5 (1.7) 1 953 39.5 (1.9) 0.42 8,864 39.5 (1.9) 0.17
Birthweight (g)
(mean, SD)
2 753 3449.6 (514.1) 1 900 3400.0 (538.7) 0.002 8,746 3406.2 (546.7) <0.001
Fat mass (g)
(mean, SD)
2 753 17462.3 (9836.2) 1 670 19661.2 (11434.4) <0.001
Ultrasound fatty liver
(N, %)
1 215 25 (2.1) 381 11 (2.9) 0.34
Ultrasound liver volume
(cm3) (median, IQR)
1 215 1581.1 (1305.8, 1856.5) 450 1588.6 (1302.1, 1875.9) 0.94
Ultrasound shear
velocity (m/sec)
(median, IQR)
1 215 1.2 (1.1, 1.3) 382 1.3 (1.1, 1.3) 0.05
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between exposures and outcomes. Associations were
generally consistent for these three categories suggesting
that it was appropriate to combine them in the main
analysis. Additional file 1: Tables S2 and S3 show the
multivariate model results (model 4) for the assocaition of
maternal diabetes/glycosuria and pre-pregnancy obesity
with USS determined fatty liver, respectively.
There were no notable differences in the associations of
maternal pregnancy diabetes/glycosuria and maternal pre-
pregnancy BMI with offspring outcomes when offspring
concurrent BMI was used as a measure of offspring adi-
posity, compared to using DXA-assessed fat mass (model
4) (see Additional file 1: Tables S4 and S5).
Discussion
In this general population prospective birth cohort, we
used USS to determine liver pathologies including fatty
liver, estimated liver volume and shear velocity (a marker
of liver stiffness or fibrosis). There were no known cases
of liver disease in this cohort and we removed the small
number of participants who had reported continuous
harmful drinking in the previous two years. Therefore it is
reasonable that in our cohort USS fatty liver is likely to
represent NAFLD.
In our study, maternal pregnancy diabetes/glycosuria was
positively associated with a 6-fold increase in odds of
offspring NAFLD and higher shear velocity at mean age
17.8 years even when adjusting for maternal pre-pregnancy
BMI. Offspring birthweight or concurrent adiposity did not
appear to mediate this association. Maternal overweight/
obesity and pre-pregnancy BMI across the BMI distribution
were associated with greater odds of NAFLD, higher
liver volume and greater shear velocity (a measure of
liver fibrosis) in adolescent offspring, even when
adjusting for potential confounders. For these associa-
tions too, birthweight did not appear to be an important
mediator. In contrast, adjusting for offspring concurrent
adiposity attenuated these associations, suggesting
that offspring’s own adiposity mediates associations
between maternal pre-pregnancy adiposity and offspring
liver outcomes.
Little is known about the early life determinants of
NAFLD as it is a relatively newly recognised condition
and therefore has not commonly been assessed in large
epidemiological studies. Our study extends findings from
two small studies; one that reported greater IHCL con-
tent in infants of obese mothers with diabetes compared
to infants of non-obese non-diabetic mothers and the
other study reported a positive association between
maternal pre-pregnancy BMI and infants’ IHCL content
[15, 16]. These studies did not examine the association
of maternal BMI and pregnancy diabetes separately as we
have done here. Furthermore, here NAFLD was assessed
much later on in the life course, which is important in
terms of understanding any lasting effect that could result
in important adverse health outcomes.
Table 1 Comparison of maternal and offspring characteristics of participants who were included in either the USS based outcomes
and/or blood-based outcome analyses, to participants not included in either analyses but attended clinic at age 17–18 years and to
those who did not attend the clinic at age 17–18 years (Continued)
ALT (U/l)
(median, IQR)
2 359 15.0 (12.0, 19.5) 614 15.2 (11.7, 19.7) 0.60
AST (U/l)
(median, IQR)
2 359 19.6 (16.8, 23.2) 614 19.6 (16.6, 23.3) 0.35
GGT (U/l)
(median, IQR)
2 359 16.0 (13.0, 21.0) 614 16.0 (13.0, 21.0) 0.63
Haptoglobin (g/l)
(median, IQR)
2 359 1.0 (0.7, 1.3) 608 1.0 (0.7, 1.3) 0.41
Glucose (mmol/l)
(median, IQR)
2 350 5.0 (4.8, 5.2) 651 5.0 (4.8, 5.3)
Insulin (pmol/l)
(median, IQR)
2 322 39.6 (29.0, 55.7) 628 43.6 (31.0, 59.2)
Triglycerides (mmol/l)
(median, IQR)
2 350 0.8 (0.6, 1.0) 651 0.8 (0.6, 1.0)
Total cholesterol
(median, IQR)
2 350 3.7 (3.3, 4.2) 651 3.7 (3.2, 4.2)
LDLc (mmol/l)
(median, IQR)
2 350 0.3 (0.3, 0.5) 651 0.3 (0.3, 0.4)
HDLc (mmol/l)
(median, IQR)
2 350 1.2 (1.1, 1.4) 651 1.2 (1.1, 1.5)
USS Ultrasound scan, ALT alanine amino transferase, AST aspartate amino transferase, GGT gamma- glutamyltransferase, LDLc low density lipoprotein cholesterol,
HDLc high density lipoprotein cholesterol, IQR Interquartile range, SD standard deviation
*P-value for the null hypothesis of no difference compared to those included in either analysis of blood based or USS outcomes group (reference group)
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The results presented in this paper add to the growing
body of evidence suggesting that maternal pregnancy
diabetes is associated with later offspring cardiometa-
bolic health. Maternal pregnancy diabetes has been asso-
ciated with higher risk of offspring adiposity [3, 26], type
2 diabetes risk [27] and higher fasting glucose and insu-
lin in adolescence [8]. Our results suggest that the risk
of offspring NAFLD is also elevated. Sibling compari-
sons, in which siblings exposed to pregnancy diabetes
are compared to their siblings not exposed to pregnancy
diabetes, thus inherently controlling for measured and
unmeasured shared genetic and familial environment,
provide convincing causal evidence that associations of
maternal pregnancy diabetes with offspring greater fat-
ness can be attributed to a direct intrauterine mechan-
ism [26, 27]. Whilst we are unable to confidently infer
that associations observed here are causal, it is reason-
able to assume that similar intrauterine mechanisms are
driving the association with NAFLD reported here.
It has been estimated that up to half of gestational dia-
betes cases are attributable to pre-pregnancy overweight
and obesity [28] and in a systematic review and meta-
analysis it was calculated that for one unit increase in pre-
pregnancy BMI the risk of gestational diabetes increased
by 0.92 % (95 % CI: 0.73,1.10 %) [29]. Here, the association
of maternal pregnancy diabetes/glycosuria and NAFLD
remained even after adjusting for potential confounding
by maternal pre-pregnancy BMI and after accounting for
birthweight and offspring concurrent adiposity. Similarly,
adjusting for maternal early pregnancy BMI in the afore-
mentioned sibling study did not account for the higher
BMI of young men exposed to diabetes in utero compared
to their unexposed brothers [26]. This suggests that familial
adiposity, whether due to shared genetics or behaviour, is
not a main or only driver of the association between
Table 2 Multivariable associations of maternal diabetes/
glycosuria with offspring USS and blood-based markers of non-
alcoholic fatty liver disease (N = 1 215 or 2 359 as indicated)
No diabetes or
glycosuria (reference)
Diabetes/glycosuria P value
USS fatty liver
N 18/1 153a 7/62a
Model 1 1 9.07 (3.53, 23.30) <0.001
Model 2 1 6.74 (2.47, 18.40) <0.001
Model 3 1 6.57 (2.38, 18.10) <0.001
Model 4 1 6.72 (1.89, 24.00) 0.003
USS liver volume
N 1 153 62
Model 1 1 1.04 (0.98, 1.11) 0.20
Model 2 1 1.03 (0.96, 1.09) 0.45
Model 3 1 1.02 (0.96, 1.08) 0.57
Model 4 1 1.01 (0.95, 1.08) 0.70
USS shear velocity
N 1 153 62
Model 1 1 1.11 (1.06, 1.16) <0.001
Model 2 1 1.10 (1.05, 1.15) <0.001
Model 3 1 1.09 (1.05, 1.15) <0.001
Model 4 1 1.08 (1.04, 1.13) 0.001
ALT
N 2 270 89
Model 1 1 1.04 (0.95, 1.14) 0.40
Model 2 1 1.03 (0.94, 1.13) 0.50
Model 3 1 1.04 (0.94, 1.13) 0.44
Model 4 1 1.01 (0.93, 1.11) 0.76
AST
N 2 270 89
Model 1 1 1.03 (0.97, 1.09) 0.38
Model 2 1 1.03 (0.97, 1.09) 0.32
Model 3 1 1.03 (0.98, 1.10) 0.27
Model 4 1 1.03 (0.97, 1.09) 0.37
GGT
N 2 270 89
Model 1 1 1.03 (0.96, 1.11) 0.43
Model 2 1 1.03 (0.95, 1.11) 0.50
Model 3 1 1.03 (0.96, 1.11) 0.43
Model 4 1 1.01 (0.94, 1.09) 0.77
Haptoglobin
N 2 270 89
Table 2 Multivariable associations of maternal diabetes/
glycosuria with offspring USS and blood-based markers of non-
alcoholic fatty liver disease (N = 1 215 or 2 359 as indicated)
(Continued)
Model 1 1 0.98, (0.87, 1.10) 0.73
Model 2 1 0.97 (0.86, 1.09) 0.57
Model 3 1 0.97 (0.86, 1.09) 0.62
Model 4 1 0.95 (0.84, 1.07) 0.42
USS Ultrasound scan, ALT alanine amino transferase, AST aspartate amino
transferase, GGT gamma- glutamyltransferase
anumerator represents the number of offspring with USS fatty liver
Model 1: adjusted for offspring age at outcome assessment and gender
Model 2: (confounder adjusted) as model 1 plus additional adjustment for
maternal age, parity, maternal alcohol intake, highest household manual social
class and maternal pre-pregnancy BMI
Model 3: (confounder and mediator adjusted) as model 2 plus additional
adjustment for birthweight for gestational age (z scores)
Model 4: (confounder and mediator adjusted) as model 2 plus additional
adjustment for DXA-assessed fat mass, height and height squared
All estimates are geometric means (95%CI) except for the estimate for USS
fatty liver (yes/no) which is an OR (95%CI)
Patel et al. BMC Pediatrics  (2016) 16:47 Page 8 of 13
Table 3 Multivariable associations of maternal pre-pregnancy obesity status and BMI with offspring USS and blood-based markers of
non-alcoholic fatty liver disease (N = 1 215 or 2 359 as indicated)
Pre-pregnancy BMI category Per SD of BMI
Underweight/normal
(reference category)
Overweight/obese P value P value
USS fatty liver
N 15/966a 10/249a 25/1 215a
Odds ratio (95 % confidence intervals) Odds ratio (95 % confidence intervals)
Model 1 1 2.72 (1.20, 6.15) 0.02 1.66 (1.27, 2.17) <0.001
Model 2 1 2.70 (1.18, 6.17) 0.02 1.68 (1.28, 2.21) <0.001
Model 3 1 2.45 (1.06, 5.99) 0.04 1.63 (1.23, 2.17) 0.001
Model 4 1 0.36 (0.11, 1.14) 0.08 0.86 (0.58, 1.28) 0.46
USS liver volume
N 966 249 1 215
Ratio of geometric means (95 % confidence intervals) Ratio of geometric means (95 % confidence intervals)
Model 1 1 1.03 (1.00, 1.07) 0.01 1.03 (1.02, 1.04) <0.001
Model 2 1 1.03 (1.00, 1.07) 0.02 1.03 (1.02, 1.05) <0.001
Model 3 1 1.01 (0.98, 1.05) 0.04 1.02 (1.00, 1.04) 0.001
Model 4 1 0.98 (0.95, 1.02) 0.75 1.01 (1.00, 1.02) 0.19
USS shear velocity
N 966 249 1 215
Ratio of geometric means (95 % confidence intervals) Ratio of geometric means (95 % confidence intervals)
Model 1 1 1.03 (1.01, 1.06) 0.08 1.02 (1.01, 1.03) <0.001
Model 2 1 1.03 (1.01, 1.06) 0.08 1.02 (1.01, 1.03) 0.001
Model 3 1 1.03 (1.00, 1.05) 0.38 1.02 (1.00, 1.03) 0.002
Model 4 1 1.00 (0.98, 1.03) 0.46 1.00 (0.99, 1.02) 0.37
ALT
N 1 921 438 2 359
Ratio of geometric means (95 % confidence intervals) Ratio of geometric means (95 % confidence intervals)
Model 1 1 1.03 (0.98, 1.08) 0.21 1.02 (1.00, 1.04) 0.06
Model 2 1 1.03 (0.98, 1.07) 0.25 1.01 (0.99, 1.04) 0.35
Model 3 1 1.03 (0.99, 1.08) 0.19 1.02 (1.00, 1.04) 0.04
Model 4 1 0.95 (0.91, 1.00) 0.04 0.98 (0.96, 1.00) 0.05
AST
N 1 921 438 2,359 2 359
Ratio of geometric means (95 % confidence intervals) Ratio of geometric means (95 % confidence intervals)
Model 1 1 0.99 (0.96, 1.02) 0.550 1.00 (0.99, 1.01) 0.54
Model 2 1 0.99 (0.96, 1.02) 0.45 0.99 (0.97, 1.01) 0.32
Model 3 1 0.99 (0.96, 1.02) 0.60 1.00 (0.99, 1.01) 0.72
Model 4 1 0.97 (0.95, 1.00) 0.07 0.99 (0.98, 1.00) 0.05
GGT
N 1 921 438 2,359 2 359
Ratio of geometric means (95 % confidence intervals) Ratio of geometric means (95 % confidence intervals)
Model 1 1 1.02 (0.98, 1.05) 0.39 1.01 (0.99, 1.02) 0.26
Model 2 1 1.02 (0.98, 1.05) 0.38 1.00 (0.97, 1.02) 0.74
Model 3 1 1.02 (0.98, 1.06) 0.29 1.01 (1.00, 1.03) 0.16
Model 4 1 0.95 (0.92, 0.99) 0.01 0.98 (0.97, 0.99) 0.01
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maternal diabetes/glycosuria in pregnancy and offspring
NAFLD; and that maternal pregnancy diabetes/glycosuria
and offspring NAFLD are associated through other mecha-
nisms. One such mechanism may be greater offspring insu-
lin resistance, though the temporal relationship between
liver fat accumulation and insulin resistance, both hepatic
and peripheral, is yet to be clarified, and for this reason we
did not adjust for measures of lipid and glucose metabolism
in our analysis. Other potential mechanisms include epi-
genetic differences (e.g. differential DNA methylation) [30]
and differences in offspring gut microbiota [31].
Authors of two recent systematic reviews [32, 3] con-
cluded that the evidence supporting association between
gestational diabetes [32], pregnancy diabetes [3] and
greater offspring adiposity (which is strongly associated
with NAFLD) remains inconclusive due to the attenu-
ation of the association when adjusting for maternal pre-
pregnancy BMI. However, most included studies were
conducted in settings with no universal screening for
gestational diabetes, with diagnostic tests only being
offered to those at greater risk, namely overweight/obese
[1]. This would then result in over-attenuation of the
maternal diabetes and offspring outcome association
when adjusting for maternal pregnancy BMI, as has pre-
viously been demonstrated [1].
In contrast, the association of maternal pre-pregnancy
BMI with NAFLD was attenuated to the null upon adjust-
ment for offspring adiposity. This suggests that familial
characteristics (genetic or behavioural) related to family
adiposity underlie the association between maternal pre-
pregnancy BMI and offspring NAFLD as opposed to a dir-
ect intrauterine effect. These findings are also consistent
with the sibling comparison study in which no association
between maternal early pregnancy BMI and offspring BMI
at 18 years was noted when only brothers were compared,
suggesting that the positive association between maternal
and offspring BMI observed in the overall population and
in other studies may be due to confounding by shared
behaviour, environmental exposures or genes inherently
controlled for in the sibling comparison [33].
We found modest associations of maternal pre-
pregnancy BMI and pregnancy diabetes/glycosuria with
blood-based outcomes. These were broadly in agree-
ment with results for the USS-determined outcomes. In
a separate publication, based on this cohort, we have
shown that those participants with NAFLD had higher
ALT, AST, GGT and haptoglobin. That said, the rela-
tively modest associations found here are likely a result
of the liver enzymes and haptoglobin being much
cruder measures of liver fat and indeed of liver health
than USS based measures [34, 35]. USS is considered
superior to liver enzyme for the diagnosis of NAFLD
which is why we considered the USS measures to be
our primary outcomes from the outset. Despite its
shortcomings compared to other imaging modalities
such as MRI and CT scans, USS is the most feasible
and commonly used method for assessing liver fat in
large scale epidemiological studies such as ALSPAC.
Our study has limitations. Loss to follow up is common
feature of many prospective cohort studies including ours.
Although loss to follow up is an issue in terms of reduc-
tion of statistical power, it is unlikely to have biased our
results as this loss to follow up would be non-differential
i.e. offspring would be unaware of their outcomes (partici-
pants would have to know if they had NAFLD).
Information on existing maternal diabetes and pre-
pregnancy weight, height and alcohol consumption were
collected by self-reported questionnaire. This non-
differential misclassification would result in an under-
estimate of associations of interest. However, as men-
tioned earlier maternal self-reported weight was highly
correlated with maternal weight measured at the first
antenatal clinical visit (r = 0.95), which provides confi-
dence in the self-reported measures.
Due to the small numbers of women with existing dia-
betes, gestational diabetes and glycosuria these groups were
Table 3 Multivariable associations of maternal pre-pregnancy obesity status and BMI with offspring USS and blood-based markers of
non-alcoholic fatty liver disease (N = 1 215 or 2 359 as indicated) (Continued)
Haptoglobin
N 1 921 438 2 359
Ratio of geometric means (95 % confidence intervals) Ratio of geometric means (95 % confidence intervals)
Model 1 1 1.03 (0.98, 1.10) 0.96 1.02 (1.00, 1.05) 0.04
Model 2 1 1.03 (0.97, 1.09) 0.97 1.00 (0.97, 1.04) 0.79
Model 3 1 1.03 (0.97, 1.10) 0.30 1.02 (1.00, 1.05) 0.05
Model 4 1 0.96 (0.90, 1.02) 0.18 0.99 (0.97, 1.01) 0.41
USS Ultrasound scan, ALT alanine amino transferase, AST aspartate amino transferase, GGT gamma- glutamyltransferase
anumerator represents the number of offspring with USS fatty liver
Model 1: adjusted for offspring age at outcome assessment and gender
Model 2: (confounder adjusted) as model 1 plus additional adjustment for maternal age, parity, maternal alcohol intake, highest household manual social class
Model 3: (confounder and mediator adjusted) as model 2 plus additional adjustment for birthweight for gestational age
Model 4: (confounder and mediator adjusted) as model 2 plus additional adjustment for DXA-assessed fat mass, height and height squared
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combined for the analysis. The prevalence of gestational
diabetes in our cohort was low, likely due to the lack of
universal screening and it is possible that women with
glycosuria are a mixture of women with undiagnosed gesta-
tional diabetes and women with high circulating glucose
levels but below the threshold that would be used to diag-
nose gestational diabetes. We cannot rule out renal glyco-
suria though the prevalence of this condition is low.
Inclusion of women with renal glycosuria or false positive
dip stick tests would result in an underestimate of the asso-
ciation of interest. Lastly, we have previously reported that
glycosuria is related to macrosomia in this cohort [7], and
with cardiovascular death in a US study, [36] giving face
validity to its use as an assessment of hyperglycaemia.
Despite the large number of participants in our study
the numbers with diagnosed gestational diabetes was
low and we lacked information on maternal glucose
tolerance and therefore larger studies with better mea-
sures of maternal glucose tolerance are required. Differ-
ent study methods such as sibling comparison studies
(such as those conducted by Dabelea et al. [27] and
Lawlor et al. [26]) may help to determine whether these
associations are at least in part driven by intrauterine
mechanisms or are fully explained by shared familial
genetic or environmental characteristics.
USS is not the ‘gold standard’ for identifying NAFLD;
however, it is neither feasible nor ethical to undertake liver
biopsies in a large cohort of healthy people. Studies have
shown USS to accurately identify moderate to severe
steatosis compared with liver biopsy in adults and children
[37, 38] thus, our prevalence estimate for NAFLD may
reflect the moderate to severe end of the spectrum of this
disease. The small number of offspring with fatty liver re-
flects the relatively young age. The ARFI measure of liver
fibrosis used in our study is a relatively new measure, but
it has been validated in a small number of clinical studies
[39, 40]. Importantly, we have looked at a range of out-
comes, including blood-based and those measured by
USS, which can be considered to be indicators of NAFLD
or its liver complications, which counters some of the
limitations of not having gold standard biopsy out-
comes. Even though this is the largest study to date
assessing the association of maternal pregnancy BMI
and diabetes/glycosuria with NAFLD in an adolescent
population; the number of offspring with NAFLD was
small though on the lower end of range compared to
a similar population [41].
Conclusions
In summary, our study adds to the small body of evi-
dence of the early life origins of NAFLD and suggests
that maternal pregnancy diabetes/glycosuria is associated
with greater risk of offspring NAFLD and higher liver
shear velocity (a marker of liver stiffness) even when
accounting for potential mediation by offspring concurrent
adiposity. Conversely, maternal pre-pregnancy BMI was no
longer associated with offspring NAFLD when accounting
for offspring adiposity. Results suggest that maternal preg-
nancy diabetes/glycosuria is associated with offspring
NAFLD through mechanisms other than offspring’s own
adiposity. These results add to the literature linking NAFLD
and diabetes and demonstrate that the two may share
common antecedents. Results also suggest that maternal
pregnancy diabetes/glycosuria is associated with offspring
NAFLD through mechanisms other than offspring’s own
adiposity. Finally, this study adds to the growing body of
evidence demonstrating the importance of maternal health
in pregnancy and its associations with long term health in
the next generation.
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